Recognition of losses and other items arising from the termination of a supply agreement with a major business partner and revision of the consolidated full-year earnings forecast for the fiscal year ending March 2027
Terumo BCT, a wholly owned subsidiary of TERUMO CORPORATION
Plasma collection centers operated by CSL Plasma in the United States, source plasma collection systems, manufacturing equipment and machinery, product technology and other related assets at production facilities in the United States
The parties agreed to terminate the supply agreement with CSL Plasma after the end of the transition period agreed between them, resulting in a review of the future earnings plan for the Terumo BCT-related business.
An aggregate loss of approximately US$610 million (approximately ¥97.5 billion) is expected. This comprises approximately US$450 million (approximately ¥72.0 billion, with no cash outlay) in impairment losses on related assets and approximately US$160 million (approximately ¥25.5 billion) in operating losses during the transition period and costs associated with terminating the agreement and restructuring the business.
The consolidated financial results for the fiscal year ending March 2027 (1 April 2026 to 31 March 2027)
The consolidated full-year earnings forecast for the fiscal year ending March 2027 was revised. Revenue was revised from ¥1,239,000 million to ¥1,229,500 million, operating profit from ¥257,500 million to ¥160,000 million, and profit for the year attributable to owners of the parent from ¥193,100 million to ¥120,000 million. The changes in operating profit and profit for the year were both negative 37.9%.
Based on the transition plan and transition period agreed between the parties, the company will proceed with procedures for terminating the agreement. It will continue to invest management resources in the blood and cell technologies field, its core business.
| Item | Details |
|---|---|
| Event name | Recognition of losses and other items arising from the termination of a supply agreement with a major business partner and revision of the consolidated full-year earnings forecast for the fiscal year ending March 2027 |
| Date of occurrence | 8 October 2026 |
| Subject Entity | Terumo BCT, a wholly owned subsidiary of TERUMO CORPORATION |
| Target Locations / Products | Plasma collection centers operated by CSL Plasma in the United States, source plasma collection systems, manufacturing equipment and machinery, product technology and other related assets at production facilities in the United States |
| Cause | The parties agreed to terminate the supply agreement with CSL Plasma after the end of the transition period agreed between them, resulting in a review of the future earnings plan for the Terumo BCT-related business. |
| Amount of Impact on Business Performance | An aggregate loss of approximately US$610 million (approximately ¥97.5 billion) is expected. This comprises approximately US$450 million (approximately ¥72.0 billion, with no cash outlay) in impairment losses on related assets and approximately US$160 million (approximately ¥25.5 billion) in operating losses during the transition period and costs associated with terminating the agreement and restructuring the business. |
| Accounting period in which recognized | The consolidated financial results for the fiscal year ending March 2027 (1 April 2026 to 31 March 2027) |
| Impact on Earnings Forecast | The consolidated full-year earnings forecast for the fiscal year ending March 2027 was revised. Revenue was revised from ¥1,239,000 million to ¥1,229,500 million, operating profit from ¥257,500 million to ¥160,000 million, and profit for the year attributable to owners of the parent from ¥193,100 million to ¥120,000 million. The changes in operating profit and profit for the year were both negative 37.9%. |
| Outlook | Based on the transition plan and transition period agreed between the parties, the company will proceed with procedures for terminating the agreement. It will continue to invest management resources in the blood and cell technologies field, its core business. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following the agreement to terminate the supply agreement with CSL Plasma, the company revised the future earnings plan for the Terumo BCT-related business to reflect impairment losses on related assets, operating losses during the transition period, and costs associated with the termination of the agreement and business restructuring.